Navigation Links
Drug prevents seizure progression in model of epilepsy
Date:5/4/2009

PITTSBURGHCarnegie Mellon University researchers have identified a new anticonvulsant compound that has the potential to stop the development of epilepsy. The findings are published in the March issue of the journal Epilepsia.

The research discovery builds on previous work identifying a specific molecular target whose increased activity is associated with seizure disorders, a potassium channel known as the BK channel.

"We have found a new anticonvulsant compound that eliminates seizures in a model of epilepsy," said Alison Barth, associate professor of biological sciences at Carnegie Mellon's Mellon College of Science. "The drug works by inhibiting ion channels whose role in epilepsy was only recently discovered. Understanding how these channels work in seizure disorders, and being able to target them with a simple treatment, represents a significant advance in our ability to understand and treat epilepsy."

Epilepsy is a neurological disorder marked by abnormal electrical activity in the brain that leads to recurring seizures. A person who has a first seizure is statistically much more likely to have a second, and with each subsequent seizure, the chance of having another seizure grows. A person is often diagnosed with epilepsy after having two or more seizures that have no other apparent cause.

In prior studies, Barth and colleagues were the first to link BK channels, ion channels that allow electrically charged potassium ions to move out of cells, to sporadic epilepsy. Previous studies had shown that these channels were genetically altered in a few rare individuals who suffer from the disease, but Barth and colleagues demonstrated that seizures themselves could lead to the same alterations in BK channel function. Potassium ions move through the channels, starting and stopping the electrical impulses that allow neurons to communicate with one another. The Carnegie Mellon researchers found that after a first seizure, BK channel function was markedly enhanced. As a result, the neurons became overly excitable and were firing with more speed, intensity and spontaneity, leading Barth to believe that the abnormal increased activity of the channels might play a role in causing subsequent seizures and the emergence of epilepsy.

In the current study, Barth tested this theory by blocking the ion channels using a BK-channel antagonist called paxilline. Using an experimental model for epilepsy, Barth asked whether paxilline could reduce or prevent experimentally induced seizures, as it could normalize aberrant brain activity induced by previous seizures. Remarkably, Barth and colleagues Jesse Sheehan and Brett Benedetti discovered that the compound was effective at completely blocking subsequent seizures.

"The drug is orally available, and works in the low nanomolar range," said Barth, noting that these characteristics, which mean the drug is effective in low concentrations and can be taken as a pill, make it an especially promising compound for treatment in epilepsy patients. While most anticonvulsants currently used to treat epilepsy work to directly inhibit the activity of neurotransmitters that causes seizures, few compounds interact with specific ion channels, especially potassium channels.

The researchers believe that targeting the BK channels and the abnormal brain activity that they induce might one day be used as a way to prevent the progression of seizure disorders over time, thus attacking the root cause of epilepsy.

According to Barth, the next steps will be to further investigate paxilline to see whether it is an effective anticonvulsant treatment for multiple types of seizures. The investigators continue to look at how BK channels are regulated by seizures to better understand the development of epilepsy.


'/>"/>

Contact: Jocelyn Duffy
jhduffy@andrew.cmu.edu
412-268-9982
Carnegie Mellon University
Source:Eurekalert

Related biology news :

1. Sexual harassment from males prevents female bonding, says study
2. Targeted drug therapy prevents exercise-induced arrhythmias
3. Alzheimers disease therapeutic prevents long-term damage from TBI in pre-clinical studies
4. Modern lifestyle prevents tooth decay
5. Decreasing insulin resistance prevents obesity-related cardiovascular damage
6. Exercise increases brain growth factor and receptors, prevents stem cell drop in middle age
7. Geisinger research: Antimalarial drug prevents diabetes in arthritis patients
8. Resveratrol prevents fat accumulation in livers of alcoholic mice
9. Anti-cancer drug prevents, reverses cardiovascular damage in mouse model of premature aging disorder
10. Chemical compound prevents cancer in lab
11. A compound extracted from olives inhibits cancer cells growth and prevents their appearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... HILLS, Mich. , Dec. 15, 2016  There ... unlocking car doors or starting the engine. Continental will ... in Las Vegas . Through the ... (Passive Start and Entry) and biometric elements, the international ... field of vehicle personalization and authentication. "The ...
(Date:12/8/2016)... 8, 2016 Market Research Future published a half cooked ... Mobile Biometric Security and Service Market is expected to grow over ... Market Highlights: ... Mobile Biometric Security and Service ... increasing need of authentication and security from unwanted cyber threats. The ...
(Date:12/7/2016)... AVIV, Israel , December 7, 2016 ... with the expansion of its patent portfolio, which grew to over 40 ... , , ... by its recently filed patent entitled " System, Device, and ... covers technology that enables device makers to forego costly hardware components needed ...
Breaking Biology News(10 mins):
(Date:1/23/2017)... Jan. 23, 2017  Alkahest Inc. ("Alkahest"), a ... neurodegenerative diseases and other age-related conditions, announced today ... as Chief Medical Officer. In this role, Dr. ... activities at Alkahest and serve on the Executive ... served as Executive Director at Dynavax, where he ...
(Date:1/21/2017)... , ... January 21, 2017 , ... ... endeavors to bring to market a pioneering medical device for the treatment of ... an engagement contract with Emergo, a global regulatory consultancy that helps companies like ...
(Date:1/20/2017)... ... January 20, 2017 , ... The two newest companies ... options for patients. Vironika, a spin out from The Wistar Institute, and Sanguis, launched ... space at 3624 Market Street. , Vironika is developing a treatment for a ...
(Date:1/19/2017)... Research and Markets has announced the addition of the ... Global Opportunity Analysis and Industry Forecast, 2014-2022" report to their ... Cancer ... reach $15,737 million by 2022 from $6,521 in 2015, growing at ... Omic technologies segment accounted for more than half of the revenue ...
Breaking Biology Technology: